REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.)Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/26/07 - 20070172490 - Leukocyte stimulation matrix The present invention relates to a leukocyte stimulation matrix for the simulation of leukocytes and/or the induction of an immunological tolerance comprising a) at least one carrier, b) a soluble matrix for embedding at least one component for generating a leukocyte stimulation and/or the induction of an immunological tolerance, and ... 07/19/07 - 20070166317 - Microparticles The present invention relates to microparticles formed from polymer materials and comprising a peptide anchored thereto for binding to a cell surface receptor, for delivering agents to cells and to a method of making such microparticles. ... 07/19/07 - 20070166316 - Tumor-derived biological antigen presenting particles Disclosed is a biological anti-tumor approach that delivers specific antigen stimulation in the presence of co-stimulatory signals to the immune system. Tumor cells are engineered such that processed antigens and co-stimulatory molecules are incorporated into virus-like particles capable of modulating immune responses without cellular entry and nucleic acid genomic host ... 07/12/07 - 20070160620 - Immune responses using compositions containing stress proteins The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino ... 06/28/07 - 20070148183 - Chemically programmable immunity The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in ... 06/28/07 - 20070148182 - Formulation of antigen The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may ... 06/28/07 - 20070148181 - Ganglioside based vaccine compositions for subcutaneous administration Vaccine compositions in which gangliosides and the OMP of N. meningitidis were combined to form very small size proteoliposomes (VSSP) to be administered subcutaneously are described, these compositions do not require the use of any additional adjuvant. The described compositions allow the immunological treatments with gangliosides, particularly N-AcGM3/VSSP and N-GcGM3/VSSP, ... 06/21/07 - 20070141071 - Hot melt coating by direct blending and coated substrates A method of coating a pharmaceutical substrate which is not a hot-melt coating by fluid bed method comprises applying a molten coating material to the pharmaceutical substrate wherein the substrate is coated with the coating material; optionally applying to the coated substrate the same or different molten coating material, and ... 06/14/07 - 20070134259 - Methods and compositions for pharmacologially controlled targeted immunotherapy The present invention relates generally to methods and compositions for targeted immunotherapy. More specifically, the present invention relates to immuno-targeted therapies, using heteromultivalent compounds to mediate the binding of an endogenous effector molecule such as an antibody to target molecules including malignant cells and tissues, bacteria and viruses as well ... 06/07/07 - 20070128206 - Preventives or remedies for infection, anti-endotoxin agents, vaccine adjuvants and growth promoters A preventive or remedy for infection, an anti-endotoxin agents, a vaccine adjuvants and a growth promoter each comprising a sugar cane-derived extract as an active ingredient which agent is safe to man and animals. Also presented are foods and feeds comprising these agents. ... 05/31/07 - 20070122418 - Compositions and methods for the pulmonary delivery of aerosolized medicaments Therapeutic dried compositions are described. The composition is in solid dose form and includes a polyol and an immunogenic agent. ... 05/31/07 - 20070122417 - Immunotherapy method The present invention relates to the use of immunomodifying agents to effect change in the T helper-type 1 (TH1) or T helper-type 2 (TH2) arms of the immune response and thereby treat TH1 or TH2 mediated diseases. In particular, the present invention relates to a method of altering a specific ... 05/24/07 - 20070116709 - Microemulsions with adsorbed macromolecules and microparticles Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the ... 05/17/07 - 20070110759 - Methods The presence of aldehydic groups on proteins and lipoproteins is associated with various pathological conditions such as atherosclerosis, diabetes and alcoholic liver disease. Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants and the elderly. RSV vaccine research has been impeded because a formalin-inactivated vaccine ... 05/17/07 - 20070110758 - Method for inhibiting bacterial colonisation The present invention relates to a method for inhibiting bacterial colonisation of mucous epithelium in a biological system. The method includes the step of administering to the biological system an effective amount of a mucolytic agent and one or more of colostrum, hyperimmune milk, or a component of colostrum and/or ... 05/03/07 - 20070098734 - Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen ... 05/03/07 - 20070098733 - In ovo delivery of an immunogen containing implant The disclosure provides a method for administering an agent to an avian species by in ovo delivery of an implant releasably containing the agent. In one embodiment, the method is particularly advantageous for stimulating an immune response in a bird by in ovo administration of a biocompatible implant releasably containing ... 05/03/07 - 20070098732 - Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer The present invention relates to the use of PDT-treated cells (whole or fragments thereof) and/or supernatant thereof in the preparation of vaccines for immunoprotection or immunomodulation. More particularly, the use of PDT-treated cells (whole or fragments thereof) and/or supernatant thereof in the preparation of an immunologic compound for prevention, protection, ... 04/26/07 - 20070092526 - Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use Improved polynucleotide vaccine adjuvants and related polynucleotide vaccine formulations are disclosed which are useful in prophylactic or therapeutic vaccine and/or gene therapy-based applications. These adjuvants comprise a block copolymer and a cationic surfactant component. The inclusion of a cationic surfactant results in an increased percentage of polynucleotide that is physically ... 04/19/07 - 20070087010 - Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders Treatment and/or prophylaxis, in mammalian patients, of neurodegenerative and other neurological medical disorders is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells, preferably those derived from the patient's own white blood cells, e.g. by extracorporeal treatment of the patient's blood cells to induce apoptosis ... 04/19/07 - 20070087009 - Immunostimulant composition comprising at least one toll-like receptor 7 or toll-like receptor 8 agonist and a toll-like receptor 4 agonist The invention relates to an immunostimulant composition comprising at least one Toll-like receptor 7 or Toll-like receptor 8 agonist and a Toll-like receptor 4 agonist. The inventive composition can also comprise a vaccine antigen. ... 04/05/07 - 20070077253 - Immunogenic compositions and methods of use Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic ... 03/29/07 - 20070071765 - Compositions for immunotherapy and uses thereof The present invention relates to a method of eliciting a cytotoxic T lymphocyte response to an antigen in an animal, the method comprising pulsing mannose receptor-bearing antigen presenting cells in vitro or ex vivo with a conjugate comprising an antigen and a carbohydrate polymer comprising mannose, wherein said carbohydrate polymer ... 03/15/07 - 20070059318 - Lipid nano particulates containing antigens as cancer vaccines The present invention provides compositions and method for increasing the immunogenicity of antigens such as tumor antigens. The compositions comprise liposomes such that they are suitable for targeting denderitic cells. The compositions preferably comprise at least 50% liposomes which are less than 120 nm. The liposomes comprise a cationic lipid ... 03/15/07 - 20070059317 - Potent immunostimulants from microalgae Immunostimulatory polysaccharides can be preferentially extracted from food-grade microalgae using an aqueous ethanol extraction procedure. The resulting preparations exhibit extremely potent immunostimulatory activity. The preferential extraction of these immunostimulatory polysaccharides is dependent on the concentration of ethanol used and the extraction temperature. The most efficient conditions are 50% ethanol concentration ... 03/08/07 - 20070053919 - Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions A composition for eliciting a T-cell mediated immune response in a subject includes transfer factor from at least two different types of source animals. For example, the composition may include mammalian transfer factor and nonmammalian transfer factor. An example of the composition includes a combination of a colostrum-derived product, which ... 03/08/07 - 20070053918 - Injectable depots consisting of liposomal aggregates for the delivery of active substances The invention relates to formulations of liposomes and polymers for the production of an injectable depot of active substances, which has sustained release and effect in a mammal organism. ... 03/01/07 - 20070048327 - Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy Methods of enhancing immune response to an immunogen in a subject are disclosed. Also disclosed are methods of reducing the sensitivity to an allergen in a subject. The methods comprise the administration of an immunomodulatory compound in specific dosing regimens that result in enhanced immune response or reduced sensitivity. ... 02/22/07 - 20070041986 - Synthetic polysaccharide antigens for immunological intervention in disease Provided are synthetic polysaccharide antigens (SPAs) with anti-inflammatory or inflammatory immunomodulatory properties, depending on their structure. Also provided are compositions comprising these SPAs, and methods of using these SPAs and compositions to either prevent or treat inflammatory pathologies, or diseases or conditions susceptible to treatment with inflammatory immunomodulators, by using ... 02/15/07 - 20070036807 - Compositions comprising structurally stable conjugate molecules The present invention provides compositions comprising conjugate molecules that are structurally stable at a temperature of between about 2 degrees C. and 8 degrees C. In some examples, a conjugate molecule comprises an antigen, such as an allergen. In some examples, a conjugate molecule comprises the Ragweed antigen Amb a ... 02/08/07 - 20070031441 - Immunotherapy based on dendritic cells Dendritic cells are exposed to at least one bacterial strain in particular bacterial species present in the human commensal flora. The bacterial strain may be a Lactobacillus and/or Bifidobacterium and/or salmonella strain. The exposed dendritic cells or a formulation, pharmaceutical or vaccine comprising such dendritic cells may be used in ... 02/01/07 - 20070026006 - Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody ... 02/01/07 - 20070026005 - Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere Disclosed is a vaccine composition including a pathogenic antigen and IL-12 encapsulated in controlled release microspheres. Also, the present invention discloses a method of enhancing the adjuvant effect of IL-12 by employing an IL-12 adjuvant encapsulated in controlled release microspheres. IL-12, used as an adjuvant for a co-administered vaccine antigen ... 01/25/07 - 20070020282 - Immunstimulating lipid formulation A pharmaceutical formulation for parenteral or mucosal administration of antigens and/or vaccines to humans and animals, comprising monglyceride preparations having at least 80% monoglyceride content and where the acyl group contains from 6 to 24 carbon atoms, together with fatty acids where the number of carbon atoms may be varied ... 01/18/07 - 20070014806 - Universally applicable blood plasma A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. ... 01/18/07 - 20070014805 - Immuno-adjuvant emulsion The invention relates to an oil-in-water adjuvant emulsion which comprises at least: squalene, an aqueous solvent, a polyoxyethylene alkyl ether nonionic surfactant, a hydrophobic nonionic surfactant, which emulsion is thermoreversible, and wherein 90% of the population by volume of the oil drops has a size less than 200 nm. The ... 01/18/07 - 20070014804 - Peptidic nanoparticles as drug delivery and antigen display systems Described is a new type of nanoparticle using the concept of self-organization of a single continuous chain to form peptidic nanoparticles. In particular, nanoparticles of the invention consist of aggregates of a continuous chain comprising two peptidic oligomerization domains connected by a linker segment. Preferred are coiled-coil oligomerization domains with ... 01/11/07 - 20070009542 - Method and device for transdermal immunization The present invention relates to methods and device for transdermal immunization. More particularly, the invention relates to a device for effective topical administration of antigens comprising an apparatus that generates micro-channels in the skin of a subject. The delivery system is useful for immunization against bacterial, viral, and fungal antigens ... 01/04/07 - 20070003564 - Diluent for immunohistochemistry An embodiment of the invention is directed to a method and diluent for stabilizing biomolecules, comprising Tris and a polyhydroxy carbohydrate selected from the group consisting of mannitol and trehalose. The diluent may optionally include casein added as a background blocking protein. The diluent may optionally include sodium azide as ... 01/04/07 - 20070003563 - Multivalent entrain-and-amplify immunotherapeutics for carcinoma The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying ... 01/04/07 - 20070003562 - Glurp-msp3 fusion protein, immunogenic compositions and malarial vaccines containing it The present invention relates to the protection against malaria. More particularly, the invention pertains to a chimeric molecule comprising at least one moiety from the Glutamate-rich protein (GLURP) and one second moiety from the Merozoite surface protein 3 (MSP3) of Plasmodium falciparum, wherein said chimeric molecule is able to induce ... 12/28/06 - 20060292163 - Phytol derived immunoadjuvants and their use in vaccine formulations This invention relates to a novel immunoadjuvant, an adjuvant component, and vaccines containing the adjuvant component. The adjuvant includes phytol or a phytol derivative. The adjuvant component, when combined with a soluble or particulate antigen, provides a vaccine with an enhanced ability to induce both humoral and cytotoxic immune responses ... 12/07/06 - 20060275312 - Molecule We describe an Fve polypeptide being a fragment, homologue, variant or derivative of Fve protein, which comprises at least one biological activity of Fve protein. Uses of such a polypeptide, etc, and nucleic acids encoding these, in the treatment and prevention of allergy and cancer are also disclosed. ... 11/23/06 - 20060263380 - Il-12 as an adjuvant for bordetella pertussis vaccines This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided. ... 11/23/06 - 20060263379 - Il-12 as an adjuvant for bordetella pertussis vaccines This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided. ... 11/23/06 - 20060263378 - Nucleic acids and proteins from streptococcus pneumoniae Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described. ... 11/23/06 - 20060263377 - Surface protein of leptospira The invention relates to Leptospiral surface proteins, and the nucleic acid molecules which encode them. Various uses are described, including immunoprophylactic, diagnostic and therapeutic methods. ... 11/23/06 - 20060263376 - Pharmaceutical composition comprising pim-activated nkt cells, and use thereof in therapy The invention concerns a pharmaceutical composition comprising at least a PIM-activated NKT cell and the use of at least one PIM and/or a PIM-activated NKT cell for treating a disease for which a granulomatous type of immune response is desired. ... 11/16/06 - 20060257419 - Il-12 as an adjuvant for bordetella pertussis vaccines This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided. ... 11/16/06 - 20060257418 - Vaccine This invention relates to three newly-identified, distinct groups of antigenic peptides [LB1(f) peptides] from the same region of the P5-like fimbrin protein discovered using sequence data from the fimbrin protein of many Haemophilus influenzae strains. The invention additionally provides chimeric polypeptides that carry one or more representatives of such peptides ... 11/16/06 - 20060257417 - Vaccine antigens of moraxella The present invention relates to antigens of Moraxella, in particular, Moraxella bovis, nucleic acid sequences encoding these antigens and formulations for use in raising an immune response against Moraxella. ... 11/16/06 - 20060257416 - Materials and methods for improved vaccination The invention relates to materials and methods for improved vaccination strategies and in particular to the use of lentivirus comprising nucleic acid encoding an antigen, or antigen presenting cells transduced with such lentivirus, to stimulate immune responses against the encoded antigen, in heterologous prime-boost vaccination regimes. ... 11/16/06 - 20060257415 - Adjuvants A method is provided for inducing the adaptive immune response of a patient to an antigen comprising administering to the patient an effective amount of a flagellin protein or peptide fragment thereof to induce an adaptive immune response to said antigen. ... 11/16/06 - 20060257414 - Mycoplasma gallisepticum formulation The present invention provides a protective formulation that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes. The formulation comprises a protective amount of live MG strain K5054 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma gallisepticum infection in birds of the ... 11/16/06 - 20060257413 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of ... 11/09/06 - 20060251664 - Method for the identification of epitopes related to immunogenicity in biopharmaceuticals The present invention relates to a method for identifying peptides involved in immunogenicity comprising the steps of a) providing cells expressing antigen presenting receptors (APR) in a number providing 0.1 to 5 ug of APR molecules, b) contacting the cells from (a) with a source of immunogenic peptides, c) isolating ... 11/02/06 - 20060246086 - Virulence genes and proteins from brucella melitensis, and their use A series of genes from Brucella spp are shown to encode products which are implicated in virulence. The identification of these genes therefore allows attenuated microorganisms to be produced. Furthermore, the genes or their encoded products can be used in the manufacture of vaccines for therapeutic application. ... 11/02/06 - 20060246085 - Methods for manipulating satiety Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging ... 11/02/06 - 20060246084 - Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins Disclosed are compositions, including LcrV antigenic polypeptides, vaccines and antibodies, as well as associated methods for treating and/or preventing Yersinia infection in a host. The invention further provides immunomodulatory LcrV proteins and polypeptides comprising TLR2 and IFN-γR-IFN-γ-binding sequences that stimulate host anti-inflammatory responses and repress pro-inflammatory responses. ... 11/02/06 - 20060246083 - Protective antigen of group a streptococci The present invention provides the discovery of a new Streptococcus protective antigen (herein designated Spa) which has been identified and isolated from Streptococci. Spa is a surface antigen distinct from M protein which evokes opsonic antibodies that are protective against multiple serotypes of streptococci. The invention further provides isolated Spa ... 11/02/06 - 20060246082 - Therapeutic peptides and method A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of sepsis, septic shock or sepsis-like conditions. ... 11/02/06 - 20060246081 - Methods and compositions for polytopic vaccination The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a ... 11/02/06 - 20060246080 - Multipathogen and monopathogen protection against the bacterial and viral infections associated with biological warfare, cardiac diseases, and cancers A method for developing vaccines and treatments against pathogens associated with biological warfare, cardiac disease, cancer, and emerging infectious diseases is to analyze the sequences of proteases of the pathogens and determine which peptide antigens will be useful in treating or preventing the effects of one or more pathogens as ... 10/26/06 - 20060240030 - Anti-hiv immunogenic formulation and process for preparation thereof A process is disclosed for preparation of a immunogenic peptide mixture in a single synthesis. The peptide mixture collectively represents the in vivo variability seen in immunogenic epitopes from an HIV pathogen. The mixture is termed a hypervariable epitope construct (HEC). Immunization with a HEC evokes broadly reactive immunity against ... 10/19/06 - 20060233816 - Use of plant oil-bodies in vaccine delivery systems The present invention relates to the use of oil bodies as a vaccine adjuvant and delivery system for administration of vaccines by parenteral, mucosal (oral, nasal, pulmonary) and transdermal routes. In addition, the present invention relates to methods of eliciting an immune response in an animal by administering oil body-antigen ... 10/19/06 - 20060233815 - Agents for protection from neointimal formation in grafts comprising an nfkappab decoy The present invention provides methods for using NFκB decoys to regulate (suppress) transcription activated by NFκB, and to suppress neointimal formation in grafts. Furthermore, the present invention relates to agents for protection from intimal thickening in vascular grafts that comprise NFκB decoys. ... 10/12/06 - 20060228369 - Stabilization and preservation of temperature-sensitive vaccines The present invention relates to the use of temperature protective agents to protect temperature sensitive vaccines. Such agents can be used to protect vaccines from degradation that results from exposure to freezing conditions or hot environments. Such agents can also be used to help reduce or prevent degradation or contamination ... 10/05/06 - 20060222655 - Compositions and methods for preventing and treating endotoxin-related diseases and conditions The invention provides pharmaceutical compositions for preventing and treating endotoxin-related diseases and conditions, as well as methods for making and using such compositions. ... 10/05/06 - 20060222654 - Methods and compounds for raising antibodies and for screening antibody repertoires The present invention relates to compositions and methods for raising antibodies generally comprising 1) providing highly immunogenic vesicles bearing at least one target antigen and 2) immunizing animals with the said antigen-bearing vesicles to induce antigen-specific antibody responses. The invention also relates to methods of screening antibody repertoires comprising 1) ... 09/14/06 - 20060204510 - Bv8 nucleic acids and polypeptides with mitogenic activity The present invention provides methods of using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival. Also provided herein are methods of screening for modulators of Bv8 activity. Furthermore, methods of treatment using Bv8 polypeptides are provided. ... 09/14/06 - 20060204509 - Accelerated cd8+ t-cell memory after dendritic cell vaccination Disclosed are compositions and methods for Here, it is shown that vaccination with peptide-coated dendritic cells (DC) generated antigen-(Ag)-specific CD8+ T-cells with the phenotype and function of memory T-cells as early as 4-6 days after immunization. These memory-like CD8+ T-cells underwent vigorous secondary expansion, resulting in rapid generation of elevated ... 09/14/06 - 20060204508 - Treatment of autoimmune diseases using an activator for the notch signalling pathway A product is disclosed comprising i) a modulator of the Notch signalling pathway; and ii) an autoantigen or bystander antigen, or a polynucleotide coding for an autoantigen or bystander antigen; as a combined preparation for simultaneous, contemporaneous, separate or sequential use for modulation of immune response. ... 09/14/06 - 20060204507 - Method for generating an immune response and reagents therefor Isolated peptides are disclosed which, when processed, generate a coordinated immune response. ... 09/07/06 - 20060198850 - Pharmaceutical formulation and a method of making same The methods of the present invention and the formulations made from those methods, allow the stable integration of multiple actives within a single formulation. The solubilisation of an active in a suitable solvent and the subsequent adsorption onto a sorbing medium provide effective protection for the active from any adverse ... 08/31/06 - 20060193870 - Compositions and methods for the therapy and diagnosis of colon cancer Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. ... 08/31/06 - 20060193869 - Methods and compositions for induction or promotion of immune tolerance The invention provides non-immunostimulatory polynucleotide antigen conjugates and methods for treating unwanted immune reactions in individuals using the non-immunostimulatory polynucleotide antigen conjugates. ... 08/17/06 - 20060182754 - Abundant extracellular products and methods for their production and use Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a ... 08/17/06 - 20060182753 - Vaccines The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses. ... 08/17/06 - 20060182752 - Tri-block polymers for nanosphere-based drug or gene delivery Biocompatible non-toxic polyarylate triblock copolymers having an A-B-A structure wherein each A is a water-soluble, hydrophilic polymer end block and the B middle block is an polyarylate oligomer. The polymers spontaneously self-assemble to form low CAC nanospheres having utility as transfection agents for gene delivery. ... 08/10/06 - 20060177459 - Treatment and diagnosis of infertitlity using tgfbeta or activin A method of treating an infertility condition in humans or mammals, by exposure of a prospective mother to TGFβ or derivative or analog of TGFβ. The exposure is advantageously in conjunction with one or more antigens of a prospective father so that a hyporesponsive immune reaction is mounted to the ... 08/10/06 - 20060177458 - Compositions of cpg and saponin adjuvants and uses thereof Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody production are disclosed. Also described are immune adjuvant compositions comprising immunostimulatory oligonucleotides and saponin adjuvants, as well as methods for increasing an immune response using the same. ... 07/13/06 - 20060153859 - Ganglioside-klh conjugate vaccine with qs-21 This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, ... 07/13/06 - 20060153858 - Method of inducing a ctl response Disclosed herein are methods for inducing an immunological CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunologic CTL response in a mammal and the level ... 06/22/06 - 20060134125 - Purification of antigen-specific t cells A new method to capture, purify and expand antigen-specific T lymphocytes has been developed using magnetic beads coated with recombinant MHC class I molecules. This method was optimized using homogenous populations of naive T cells purified from mice transgenic for the 2C T cell receptor (TCR). These T cells were ... 06/22/06 - 20060134124 - Immunosuppression The invention herein described relates to a method to improve the tolerance of a mammal, preferably a human, to a xenograft through immunisation of the recipient mammal with an immunogen comprising both a B cell epitope derived from porcine polypetides and T cell epitope. The invention also encompasses immunogenic compositions ... 06/08/06 - 20060121046 - Compositions and methods for wt1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that ... 06/01/06 - 20060115487 - Allogeneic cellular immunotherapy for invasive pulmonary aspergillosis (ipa) A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells. In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion. ... 05/18/06 - 20060104987 - Novel nucleic acid molecules correlated with the rhesus weak d phenotype The present invention relates to novel nucleic acid molecules encoding a Rhesus D antigen contributing to the weak D phenotype which are characterized by one or a combination of missense mutations or by a gene conversion involving exons 6 to 9 of the RHD and RHCE genes. The present invention ... 05/18/06 - 20060104986 - Yeast-dendritic cell vaccines and uses thereof Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a ... 05/11/06 - 20060099217 - Eraap modulators regulate immune responses An immune response is modulated by selectively inhibiting ERAAP (an acronym for ER aminopeptidase associated with antigen processing) and confirming a resultant immune response modulation. More particularly, the method comprises contacting a patient determined to be in need of immune response modulation with a physiologically acceptable dosage composition comprising an ... 05/11/06 - 20060099216 - Peptide delivery Disclosed is a chimaeric polypeptide comprising: a binding portion having specific binding affinity for a eukaryotic target cell surface component and an effector portion comprising an amino acid sequence capable of exerting a biological effect; whereby binding of the polypeptide to the cell surface component induces internalisation of at least ... 05/11/06 - 20060099215 - Walnut and ryegrass allergens A 30 kDa ragweed complete pollen extract disulfide protein allergen has been purified from ragweed pollen. IgE immunoblots with sera of ragweed, walnut and ryegrass sensitive patients indicated that the 30 kDa protein is a major allergen. The 30 kDa protein finds use in allergy testing and immunotherapy regimens. ... 04/20/06 - 20060083749 - Compositions and methods for the therapy and diagnosis of breast cancer Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. ... 04/20/06 - 20060083748 - Calixarenes for use as excipient for an active substance The invention relates to an active substance excipient system, wherein the excipients are selected from the group of calixarenes or resorcinarenes. Said macromolecular excipients serve for transport of the active substance to the location of action and to a dosage and time-defined release of the same there. Metabolism, kinetics and ... 04/06/06 - 20060073157 - Attenuated live neospora vaccine The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals. ... 04/06/06 - 20060073156 - Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract Pharmaceutical compositions for the treatment of infections by pathogens of the urinary tract and, more particularly, compositions containing fosfomycin optionally associated with N-acetylcysteine. ... 03/30/06 - 20060067943 - Stabilization of alum-adjuvanted immunologically active agents A composition and method for formulating and delivering an adjuvanted immunological active agent, especially a vaccine, wherein adjuvant coagulation and concomitant loss of vaccine efficacy enhancement is mitigated or avoided. The adjuvanted, immunologically-active agent can be subjected to freezing, drying, freeze-drying, or lyophilization, and when reconstituted, retains a high level ... 03/30/06 - 20060067942 - Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals The invention relates to a composition of proteins, peptides and/or peptide components, to a pharmaceutical agent comprising said composition, to a method for the production of said composition, and to the use thereof in the prophylaxis or therapy of persons, animals and/or patients with pathogenic modifications and/or cellular immunodeficiencies, especially ... 03/23/06 - 20060062797 - Novel materials and methods for the treatment of alzheimer's disease patients The invention generally relates to the treatment of patients with Alzheimer's disease, at risk for Alzheimer's disease, and other neurodegenerative diseases. More specifically, embodiments of the present invention contemplate novel compositions and methods for the treatment of such patients. In one embodiment, the present invention contemplates proteins and protein variants ... 03/16/06 - 20060057152 - Helicobacter system and uses thereof Helicobacter based preparations comprising a pharmacologically active molecule of interest are disclosed, as well as methods of preparing and using said preparations. In particular, Helicobacter pylori vectors, vector plasmids and recombinant cells that include a sequence encoding a pharmacologically active molecule of interest useful in therapeutic treatments and/or vaccination against ... 03/16/06 - 20060057151 - Bmpb novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof An isolated amino acid sequence comprising the sequence set out in SEQ ID NO:2 or an amino acid sequence substantially homologous thereto, or a fragment thereof, with the proviso that the amino acid sequence in SEQ ID NO:3 is specifically excluded. ... 03/16/06 - 20060057150 - Compositions against chicken coccidiosis Prevention and treatment of coccidiosis in chicken is accomplished by administering an anti-chicken coccidiosis composition adapted for oral administration. This composition contains an antibody obtained from an egg of a chicken immunized with an antigenic outermembrane protein or an immunogenic fragment thereof as an antigen having an immunogenicity common for ... 03/09/06 - 20060051358 - Immune response assessment method The present invention includes compositions and methods for identifying T-cell epitopes independent of the subject's HLS type by simultaneously analyzing the culture for multiple parameters of immune reactivity to identify at least one epitope wherein the epitopes that elicit immune reactivity of interest in the subset are identified as targeting ... 03/09/06 - 20060051357 - Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and or a mtor inhibitor A method for inducing or modulating T or B cells tolerance to donor cells, tissue or organ in a recipient comprising administering to the recipient a LFA-1 inhibitor in combination with a costimulation inhibitor and/or a mTOR inhibitor. ... 03/02/06 - 20060045882 - Developing oral tolerance for airborne allergens A method is disclosed for developing desensitization to airborne allergens in persons suffering from allergic reactions to such substances. This desensitization is developed by orally administering airborne allergens collected from the environment which leads to allergy symptoms in the user. The illustrative embodiments collect airborne allergens in water by passing ... 02/23/06 - 20060039917 - Method for treating phantom pain by peripheral administration of a neurotoxin Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin. ... 02/23/06 - 20060039916 - Method for treating complex regional pain by peripheral administration of a neurotoxin Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin. ... 02/16/06 - 20060034854 - Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria The present invention relates to immunogenic compositions and vaccines for the prevention or treatment of Gram negative bacterial infection. Immunogenic compositions of the invention comprise transferrin binding protein and Hsf, and the combination of these two antigens have been shown to act synergistically to produce antibodies with high activity in ... 01/26/06 - 20060018916 - Compositions and methods for eliciting an immune response to gram-negative bacterial infections Compositions for eliciting an immune response against Gram-negative bacterial infections and methods of making such compositions are provided. The composition comprises glycosylated pilin, the pilin being glycosylated with the O-antigen of a target Gram-negative bacteria of interest. Methods of eliciting an immune response by administration of such compositions are also ... 01/26/06 - 20060018915 - Heteroclitic analogs and related methods Heteroclitic analogs of class I epitopes are prepared by providing conservative, semi-conservative, or non-conservative amino acid substitutions at positions 3 and/or 4 and/or 5 and/or 6 and/or 7 and/or 8 and/or 9 and/or 10 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding ... 01/19/06 - 20060013821 - Vaccine compositions and adjuvant The immune response of an animal to a target immunogen may be enhanced by use of a novel adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combination with mineral oil. The adjuvant may be used in vaccine compositions for the immunization of an animal ... 01/19/06 - 20060013820 - Antigen delivery vectors and constructs The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals. ... 01/12/06 - 20060008463 - Tumor antigen peptides derived from cyclophilin b Tumor antigen peptides derived from cyclophilins or derivatives thereof having the functionally equivalent properties; medicaments, prophylactics, or diagnostics for tumors comprising as an active ingredient such tumor antigen peptides or derivatives thereof, cyclophilins or partial polypeptides thereof, or genes encoding said cyclophilins or partial polypeptides thereof; in vitro use of ... 01/12/06 - 20060008462 - Treatment of mammalian reaction of ige interactions A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp. ... 12/29/05 - 20050287157 - Dry formulation for transcutaneous immunization A transcutaneous immunization system delivers antigen to immune cells through the skin, and induces an immune response in an animal or human. For example, a skin-active adjuvant (e.g., an ADP-ribosylating exotoxin) can be used to induce an antigen-specific immune response (e.g., humoral and/or cellular effectors) after transcutaneous application of a ... 12/29/05 - 20050287156 - Novel amine-based adjuvant An adjuvant for use in a vaccine, the adjuvant comprising one or more cationic substances such as, e.g., acyl amines comprising from 4 to 30 carbon atoms, 5 quaternary ammonium compounds derived from acyl amines, cationic acyl amides, amino acids conjugated to an acyl group, etc., and mixtures thereof. ... 12/22/05 - 20050281834 - Altered peptide ligands The present invention provides compositions comprising altered peptide ligands that elicit immune responses in a subject to a native peptide. This invention also provides methods to raise T cell populations as well as a substantially purified population of said T cells. Altered peptide ligands find application in a wide variety ... 12/22/05 - 20050281833 - Polysaccharide conjugates of biomolecules Compounds that are modified polysaccharides having pendant aldehyde functionalities are disclosed. Each of the aldehyde functionalities is attached through a linker to a position corresponding to a hydrogen atom of a different hydroxyl group of unmodified polysaccharide. Also disclosed is a method fore introducing an amine-reactive functionality into a dextran. ... 12/22/05 - 20050281832 - Methods of enhancing immune response in the intradermal compartment and compounds useful thereof The present invention relates to immunogenic compositions for intradermal delivery of an antigenic or immunogenic agent in combination with one or more excipients. The immunogenic compositions of the invention comprise an antigenic or immunogenic agent and at least one excipient which acts as an adjuvant, i.e., enhances the immune response ... 12/08/05 - 20050271674 - Methods and compositions for modulating the immune system of animals Methods and compositions are disclosed for modulating the immune system of animals. Applicant has identified that oral administration of immunoglobulins purified from animal blood can modulate serum IgG, TNF-α or other nonspecific immunity components' levels for treatment of immune dysfunction disorders, potentiation of vaccination protocols, and improvement of overall health ... 12/01/05 - 20050266012 - Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same The invention concerns compositions comprising a demethylationg agent and an antigen for inducing and enhancing antigen-specific immunity and uses thereof. The invention also concerns methods for enhancing antigen-specific immunity by administrating a demethylating agent. ... 12/01/05 - 20050266011 - Method and formulation for transdermal delivery of immunologically active agents A method for formulating an immunologically active agent and an apparatus for delivery same, the method comprising the steps of providing a bulk immunologically active agent, subjecting the bulk immunologically active agent to tangential-flow filtration to provide an immunologically active agent solution, adding at least one excipient to the agent ... 11/24/05 - 20050260216 - Vaccine The present invention relates to an isolated polypeptide useful for immunisation against self-antigens. In particular the invention relates to a self-protein that is capable of raising auto-antibodies when administered in vivo. The invention particularly relates to rendering human cytokines immunogenic in humans. The invention further relates to pharmaceutical compositions comprising ... 11/17/05 - 20050255121 - Molecules enhancing dermal delivery of influenza vaccines The present invention relates to dermal vaccine formulations, designed for targeted delivery of an immunogenic composition to a dermal compartment of skin including the intradermal and epidermal compartments. The dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, ... 11/03/05 - 20050244420 - Novel parenteral vaccine formulations and uses thereof Parenteral vaccine formulations and adjuvant compositions comprising certain salts as adjuvants are disclosed. Such parenteral vaccine formulations are used for generating an immune response in a subject following administration of the vaccine formulation or the adjuvant composition. Also disclosed is the use of these salts as adjuvants in parenteral vaccine ... 11/03/05 - 20050244419 - Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty ... 10/27/05 - 20050238652 - Human lung adenocarcinoma-related monoclonal antibody and antigen and immunaossay method which uses the same The monoclonal antibody produced by a hybridoma cell strain TRD-L1, -L2 or -L3 which is obtained by the fusion between mouse myeloma cells and spleen cells of a mouse immunized with a human lung adenocarcinoma cell secretion component reacts in a specific fashion with a glycoprotein antigen that has a ... 10/27/05 - 20050238651 - Treatment of inflammatory bowel disease Methods and compositions are disclosed for treatment of inflammatory bowel disease in a patient in need thereof based upon administration of an inducer of indoleamine 2,3-dioxygenase, a ligand of B7 antigen expressed on antigen presenting cells, or a combination thereof. ... 10/20/05 - 20050232930 - Processes for the preparation of a batch of an active pharmaceutical ingredient, a container comprising cryogranules of an allergen product, and a cryogranule of an allergen product The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation ... 10/13/05 - 20050226886 - Preferential detection of procarboxypeptidase r (thrombin activatable fibrinolyisis inhibitor) by enzyme-linked immunosorbent assay Antibodies that specifically recognize mammalian carboxypeptidase molecules are provided which are useful in diagnostic and therapeutic methods. Exemplary monoclonal antibodies (mAbs) specifically bind to pro-carboxypeptidase R (proCPR), also known as thrombin activatable fibrinolysis inhibitor (TAFI). These mAbs are useful in immunoassays, including an exemplary, sandwich enzyme-linked immunosorbent assay (ELISA) system, ... 10/13/05 - 20050226885 - Cytolysis of target cells by superantigen conjugates inducing t-cell activation A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in that at least one of the superantigen and the immune modulator is in the form of ... 10/06/05 - 20050220800 - Cytokines and cytokine receptors with reduced immunogenicity The present invention provides methods for the identification of CD4+ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no longer capable of initiating the CD4+ T-cell response. In some ... 10/06/05 - 20050220799 - Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune ... 09/22/05 - 20050208061 - Treatment of autoimmune diseases by oral administration of autoantigens The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes ... 09/22/05 - 20050208060 - Vaccine composition R2 and R3 are identical or different, and can each represent linear hydrocarbon-based chains having from 13 to 21 carbon atoms. ... 09/15/05 - 20050202031 - Flea allantoinase nucleic acid molecules, proteins and uses thereof The present invention relates to flea allantoinase proteins; to flea allantoinase nucleic acid molecules, including those that encode such flea allantoinase proteins; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid ... 09/15/05 - 20050202030 - Method of evaluating the therapeutic potential of a vaccine for mucosal administration The invention relates to a method of evaluating the therapeutic potential of a vaccination program comprising a vaccine for mucosal administration comprising one or more antigens and a vaccination protocol, the method comprising a) subjecting at least one test individual to the vaccination program, b) measuring the level of a ... 09/15/05 - 20050202029 - Family of cystatin-related chemoattractant proteins Methods are provided to modulate the trafficking of leukocytes through interactions with one or more of a class of chemoattractant proteins having a cystatin-like structure. Exemplary of proteins in this class is chemerin, which interacts with the receptor CMKLR1. The chemoattractant polypeptide, or agonists of the chemoattractant receptor, act to ... 09/01/05 - 20050191309 - Induction of antigen specific immunologic tolerance Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from ... 09/01/05 - 20050191308 - Adjuvant combinations for immunization composition and vaccines An adjuvant combination and a kit useful for immunization is provided. The kit contains an antigenic substance and an adjuvant combination of dimethyl dioctadecyl ammonium bromide (DDA-Br or DDA-Cl) with a monophosphoryl lipid. ... 08/11/05 - 20050175623 - Saponins as anticancer agent The invention described herein encompasses novel discovery of anticancer agents and its compositions comprising saponins, a group of triterpenoid and steroidal saponins found in plants including Quillaja saponaria Molina (soap tree), which are used as therapeutic compounds for the treatment and prevention of cancer diseases or as a dietary supplement ... 08/11/05 - 20050175622 - Process for the hydrolysis of milk proteins The present invention provides a composition comprising hydrolysed milk casein and, preferably non-hydrolysed whey protein in a ratio from 9:1 to 1:1 (on dry weight), which is a clear liquid at pH 4 when dissolved or present in water in an amount of 40 g/litre at 10° C. ... 08/11/05 - 20050175621 - Adjuvant composition comprising fha protein or a fragment of fha protein in its free form The invention concerns the use of the FHA protein or part of the FHA protein, in free form, as adjuvant of the immune response or as immunostimulant in a human or an animal. The invention also concerns adjuvant and immunostimulatory compositions comprising FHA protein or a fragment thereof, and the ... 07/28/05 - 20050163788 - Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is ... 07/28/05 - 20050163787 - Immunological adjuvant A pharmaceutical composition to be administered to mammals via the mucosal route consisting of a vehicle system comprising mono-/dietherglycerides conjugated with a water soluble polymer groups selected from PEG's containing 2-30 polyoxyethylene units, an antigen and optionally a bacterial toxin for the augmentation of immune responses for vaccination, immunisation, treatment ... 07/21/05 - 20050158331 - Autogenous vaccine derived from one's own hypothalamus of the brain & kidney's via a process known as liquefaction By extrapolation of tissue from the person affected, and then using the process of liquefaction, and from there creating an autogenous vaccine and injecting that vaccine 1 cc to the affected area would not only cure heart disease, strokes, renal failure, Chron's Disease, asthma, sugar diabetes and as a cure ... 07/21/05 - 20050158330 - Oil adjuvant vaccine The present invention provides a W/O/W type oil adjuvant vaccine containing an outer aqueous phase containing 0.5 wt %-20 wt % of a polyethylene glycol derivative having a molecular weight of 400-20,000, and an inner aqueous phase containing a biologically acceptable and effective amount of an antigen. The constitution of ... 07/21/05 - 20050158329 - Novel phytol derived immunoadjuvants and their use in vaccine formulations This invention relates to a novel immunoadjuvant, an adjuvant component, and vaccines containing the adjuvant component. The adjuvant includes phytol or a phytol derivative. The adjuvant component, when combined with a soluble or particulate antigen, provides a vaccine with an enhanced ability to induce both humoral and cytotoxic immune responses ... 07/21/05 - 20050158328 - Method and composition for producing a cellular allogeneic vaccine A method for the production of a cellular allogeneic vaccine, which is based upon an allogeneic APC, includes the following steps: a) isolation of an APC from a subject or providing an APC already established and/or isolated from a myeloid leukemia cell line, and b) modifying the APC with an ... 07/14/05 - 20050152915 - Method for immune response eliciting in a mammal The invention relates to immunology, in particular to methods for influencing the immune system, and may be useful in immunotherapy for diseases of humans and animals, including therapy for oncological, autoimmune, and viral diseases. The invention comprises exposure of tumor cells obtained ex vivo or pathological cells of a non-tumorous ... 07/14/05 - 20050152914 - Formulation of antigen The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may ... 06/23/05 - 20050136066 - Cellular vaccines and immunotherapeutics and methods for their preparation The present invention provides a method for enhancing the immunogenicity of weakly immunogenic or non-immunogenic cells, resulting in a cellular vaccine that can stimulate T cell activation, which in turn leads to an effective immune response. The cellular vaccines of the present invention are useful for the prevention and treatment ... 06/23/05 - 20050136065 - Use of small molecule compounds for immunopotentiation The invention provides immunostimulatory compositions comprising a small molecule immuno-poteniator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering ... 06/09/05 - 20050123550 - Molecules enhancing dermal delivery of influenza vaccines The present invention relates to dermal vaccine formulations, designed for targeted delivery of an immunogenic composition to a dermal compartment of skin including the intradermal and epidermal compartments. The dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, ... ### FreshPatents.com Support |